Skip to main content
. Author manuscript; available in PMC: 2024 Nov 29.
Published in final edited form as: Mol Pharm. 2023 Aug 8;20(9):4629–4639. doi: 10.1021/acs.molpharmaceut.3c00360

Figure 6.

Figure 6.

HER2-positive tumors had a higher SUVmean than HER2-negative tumors at 24, 48, and 72 h postinjection of [89Zr]Zr-DFO-2Rs15d. Analysis was completed using a student’s t-test. ****p < 0.0001.